Ani Pharmaceuticals (ANIP) Operating Income (2016 - 2025)
Ani Pharmaceuticals (ANIP) has disclosed Operating Income for 14 consecutive years, with $34.8 million as the latest value for Q4 2025.
- Quarterly Operating Income rose 894.13% to $34.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $111.1 million through Dec 2025, up 18922.77% year-over-year, with the annual reading at $111.1 million for FY2025, 18922.77% up from the prior year.
- Operating Income hit $34.8 million in Q4 2025 for Ani Pharmaceuticals, down from $36.2 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $36.2 million in Q3 2025 to a low of -$23.7 million in Q4 2021.
- Historically, Operating Income has averaged $4.2 million across 5 years, with a median of $4.1 million in 2021.
- Biggest five-year swings in Operating Income: plummeted 7267.07% in 2021 and later soared 894.13% in 2025.
- Year by year, Operating Income stood at -$23.7 million in 2021, then soared by 107.67% to $1.8 million in 2022, then skyrocketed by 269.56% to $6.7 million in 2023, then crashed by 165.09% to -$4.4 million in 2024, then skyrocketed by 894.13% to $34.8 million in 2025.
- Business Quant data shows Operating Income for ANIP at $34.8 million in Q4 2025, $36.2 million in Q3 2025, and $13.9 million in Q2 2025.